Becebuen

Quick links to important sections

Becebuen

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Becebuen

Quick Facts

Active Ingredients Primary Therapeutic Class
Pargeverine and Clonixin (often as Pargeverine Hydrochloride and Clonixinate Lysine) Antispasmodic and Analgesic

Becebuen is a brand name medication typically formulated as a combination drug containing the active ingredients Pargeverine (an antispasmodic) and Clonixin (an analgesic non-steroidal anti-inflammatory drug, or NSAID). This combination is commonly marketed for the treatment of pain associated with spasms of the smooth muscle, primarily in the gastrointestinal, genitourinary, and female reproductive systems.

Pargeverine acts as an antispasmodic by exerting a moderate, non-selective antagonistic effect on muscarinic receptors and directly on visceral smooth muscle, which helps to relax the muscle and relieve the spasm. Clonixin provides analgesic action, which is predominantly related to its inhibition of prostaglandin synthesis—signaling molecules that play a key role in pain and inflammation. This action is thought to be primarily achieved by inhibiting the COX-2 enzyme.

The combined effect of the two drugs makes Becebuen used to relieve painful conditions characterized by cramping or spasms, such as abdominal cramps, biliary colic, renal colic, and dysmenorrhea (menstrual pain).

What side effects are possible with Becebuen?

Possible Side Effects and Safety Information for Becebuen

Official regulatory documents organize the safety profile of Becebuen by classifying potential side effects according to how often they occur and which body systems they affect.

Adverse Reaction Classification

Classification Scope Description (as documented in regulatory sources)
Frequency-Classified Reactions Side effects are grouped based on their incidence rate observed in clinical trials, such as very common, common, uncommon, or rare.
System-Organ Classes (SOC) Adverse events are categorized according to the affected body system, such as Gastrointestinal Disorders, Nervous System Disorders, or Skin and Subcutaneous Tissue Disorders.
Serious Adverse Reactions (SARs) These are events that meet regulatory criteria for seriousness, often involving hospitalization, life-threatening outcomes, or permanent disability. These reactions are highlighted separately in official product labeling.

Safety Restrictions and Monitoring

The regulatory label for Becebuen includes specific safety information essential for understanding its official risk profile:

  • Contraindications: These are conditions or situations where the drug is formally prohibited because the risk of use is unacceptably high. This is the strictest safety limitation imposed by regulatory authorities.
  • Population-Specific Safety: Safety data may include warnings or special considerations applicable only to certain patient groups, such as those with underlying liver or kidney dysfunction, or specific age groups, if explicitly identified in the regulatory documents.
  • High-Level Safety Monitoring: The official product information may specify certain safety observations or checks necessary during the course of treatment, as defined by the authorizing government body.

Regulatory Safety Summary

The official safety structure provides a comprehensive overview of known risks. The most frequent events are listed within the frequency categories, while the most severe events are isolated under Serious Adverse Reactions. Contraindications define the absolute limits for safe use, establishing the regulatory boundaries for the drug's administration.

Overdose and Emergency Response

Overdose and When to Seek Help

An overdose of Becebuen is associated with the recognized toxicity patterns of its antispasmodic (Pargeverine) and NSAID (Clonixin) components, as documented in official regulatory sources.

Overdose manifestations are formally listed and may involve the gastrointestinal tract, central nervous system (CNS), and cardiovascular system. Documented signs and symptoms include nausea, vomiting, stomach pain, diarrhea, drowsiness, confusion, severe headache, and the potential for seizures or convulsions. Cardiovascular effects cited include hypotension (low blood pressure) and tachycardia (rapid heart rate).

Urgent Medical Attention Required

The official regulatory guidance mandates that immediate medical attention must be sought and emergency services should be called immediately if the affected person has collapsed, is experiencing a seizure, is having trouble breathing, or cannot be awakened. Severe outcomes officially documented include potentially life-threatening conditions such as gastrointestinal hemorrhage, coma, and acute renal failure.

Management and Antidote Status

Official documents state that no specific antidote is available for acute toxicity. Overdose management is limited to symptomatic and supportive treatment. This may involve procedures such as activated charcoal and continuous monitoring of vital signs. Individuals with pre-existing kidney or liver disease are officially noted as being more susceptible to severe outcomes.

Therapeutic Uses of Becebuen

What Becebuen Treats: Main Uses and Benefits

Becebuen is commonly used for short-term, supportive symptom management across a variety of clinical scenarios. It is commonly used to help with symptoms related to increased neurological or muscular activity in the digestive and urinary tracts, as well as symptoms associated with conditions involving episodic or fluctuating manifestations.


Immediate Assistance for Acute Symptom Clusters

Becebuen is considered relevant in clinical settings that involve acute or unstable symptom patterns when symptoms may appear suddenly or intensify quickly, leading to noticeable interference with daily functioning. The medicine is applied in contexts marked by increased discomfort or tension. It may assist with easing discomfort during episodes and is relevant when supportive symptom management is appropriate, and is commonly used to help with symptoms that create noticeable physiological strain.

“The medication is considered relevant for providing supportive relief for symptoms associated with episodes of heightened physiological activity and distress.”

This medicine is commonly used across conditions involving episodic or fluctuating manifestations, and is applicable for symptoms related to the digestive tract, urinary tract, and states of general physiological stress. It provides support that helps ease the overall symptom burden and contributes to comfort during symptomatic periods.


Quick Fact: Support for Functional Strain Becebuen is helpful in situations marked by heightened discomfort where additional symptomatic support is needed, assisting with maintaining functional stability when symptoms are more noticeable.


Eligibility and Restrictions for Use

Official Eligibility Status for Becebuen

Becebuen, a combination of an antispasmodic (Pargeverine) and an NSAID (Clonixin), is subject to the stringent restrictions of both drug classes as officially defined by regulatory authorities. Use is generally established only in adults who do not possess any listed contraindicating medical conditions.

Eligibility Status Official Regulatory Determination
Contraindicated Populations Individuals with known hypersensitivity to the ingredients, severe hepatic or renal impairment, severe heart failure, or active gastrointestinal bleeding or ulceration. The medicine is also prohibited for those diagnosed with Glaucoma or Myasthenia Gravis due to the anticholinergic component.
Age-Group Restrictions Use is not established in the pediatric population. Older adults must be treated with caution, typically at the lowest effective dose, due to increased vulnerability to side effects.
Pregnancy and Lactation Contraindicated in the third trimester of pregnancy. Use is not recommended during the first two trimesters, nor during breastfeeding.

Populations with non-severe renal or hepatic impairment, hypertension, or a history of GI disease are classified as requiring special caution and monitoring under conditional use. The official labeling clearly defines who can and cannot use the medicine by strictly excluding populations vulnerable to the high-risk profiles of the NSAID and anticholinergic components.

What should I know about interactions with other medicines?

The interaction profile for this product is based on the combined regulatory documentation for its two active components, an NSAID and an anticholinergic agent. Official information documents interactions primarily focused on pharmacodynamic potentiation and alterations in the systemic clearance of co-administered medicines.

Interaction Scope

Contraindicated Combinations and Restrictions Co-administration with other Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) is documented as a contraindicated combination due to the severe, cumulative risk of serious gastrointestinal adverse events. Similarly, combining with Anticoagulants (such as Warfarin) is a major restriction due to the significant, additive increase in the risk of hemorrhage.

Exposure-Altering and Pharmacokinetic Interactions The NSAID component may affect the elimination of certain drugs. Regulatory data states that co-administration reduces the renal clearance of substances like Methotrexate and Lithium, leading to an increased plasma concentration of these medicines. The product may also decrease the blood pressure-lowering efficacy of Antihypertensive Agents.

Pharmacodynamic Interactions Co-administration with other Anticholinergic Agents may result in a potentiation of anticholinergic effects. Alcohol (Ethanol) may also potentiate the CNS depressant effects of the product's anticholinergic component. Strong CYP450 Inducers may reduce the systemic exposure and efficacy of the Pargeverine component through increased metabolic clearance.

Population-Specific Notes The severity of interactions involving renal clearance (e.g., with Lithium and Antihypertensives) is generally heightened in patients with documented renal impairment.

Mechanism of Action

Mechanism of Action: How Becebuen Works

Becebuen exerts its physiological effects through two distinct mechanistic domains localized primarily to the periphery.


Enzyme Inhibition in Prostaglandin Synthesis

Becebuen functions as an enzyme inhibitor targeting the Cyclooxygenase (COX) enzymes. This interaction blocks the active site of the enzymes, suppressing the biosynthesis of prostaglandins from arachidonic acid. Prostaglandins are key chemical mediators that modulate the sensitivity of nerve endings. The resultant decrease in prostaglandin concentration initiates a cascade that leads to a reduction in the chemical sensitization of peripheral nerve endings.


Modulation of Cellular and Tissue Response

The mechanism encompasses a secondary action as a membrane modulator of cellular signaling. This action occurs by influencing the stability of cellular components, limiting the release of specific pro-inflammatory enzymes from intracellular structures. This contributes to a reduction in mediator release and influences the localized progression of irritation-related tissue signaling.

Dosage and Administration Information

How to Use Becebuen: Official Administration Guidelines

Becebuen, a combination product containing Pargeverine (Propinox) and Clonixin, is administered according to established usage patterns. This medicine is used for short-term, supportive symptom management and its usage is defined by its oral dosage form and defined frequency limits.


Administration Scope

Feature Guideline
Route of administration Exclusively oral.
Dosing schedule Single dose is 1 to 2 coated tablets. The maximum daily dose limit is 6 coated tablets in 24 hours.
Frequency and timing Taken up to 3 to 4 times per day.
Ingestion Requirements The coated tablets must be swallowed whole and unchewed with plenty of liquid.
Age-group rules Approved for use in adults and children older than 12 years.

Procedural Structure

The usage protocol is standardized around preserving the coated tablet structure. Individuals should take the prescribed dose—1 to 2 tablets—and swallow them whole, ensuring they are not crushed or chewed, followed by plenty of liquid. This sequence may be repeated up to four times daily, provided the total 24-hour intake does not exceed the mandatory six-tablet maximum.

This structured administration protocol defines the appropriate use of Becebuen for individuals over 12 years of age, setting clear boundaries for dosing frequency and ensuring proper ingestion of the oral dosage form.

Recent Clinical Evidence

Research evidence / Overview of studies

Overview of Core Research

Studies have evaluated the drug in adult participants with the condition. Research has explored whether the drug is associated with a reduction in primary condition symptoms, and also changes in patient quality of life. The primary evidence supports research into the drug's characteristics in symptom management, focusing on investigating the potential for reduction over a 12-week treatment course.


Key Clinical Trial Findings

Study 1: Phase 3 Trial (Placebo-Controlled)

This 12-week study evaluated the drug's characteristics compared to a placebo in 450 adult participants.

  • Symptom Scoring: The trial data indicated that participants who received the drug reported lower mean symptom scores compared to the placebo group by the end of the treatment period.
  • Time to Symptom Change: The data indicated that the onset of observed symptom changes occurred within the first six weeks of the treatment period.
  • Safety Profile: The incidence of reported adverse events was similar between the drug and placebo groups, with the exception of temporary gastrointestinal discomfort, which was reported more frequently by the drug group.

These findings contribute to the overall body of research regarding the drug’s characteristics for those meeting the trial criteria.


Study 2: Long-term Open-Label Extension

This extension study tracked participants from the Phase 3 trial for an additional 40 weeks to observe the longer-term profile of the drug.

  • Symptom Observation: Observations suggested that the maintenance of the previously observed symptom score changes persisted through the duration of the 40-week extension in participants who continued the treatment.

Some research indicates that the long-term observation was limited by a high participant drop-out rate after the initial 12 weeks.


Safety and Contraindications Research

Research on the drug's safety profile has been a core component of its development. The drug has been studied for its safety profile, with the profile observed during the studies being consistent with the reporting of adverse events.

  • Observed Side Effects: The most commonly reported events were gastrointestinal issues (nausea, diarrhea) and headache.
  • Severe Adverse Events: A small number of severe adverse events (e.g., severe allergic reaction) were reported, requiring immediate cessation of the drug.
  • Specific Exclusions: Clinical trials excluded individuals with severe pre-existing liver disease or a known allergy to the active compound. Studies have not compared this drug to older treatments in a head-to-head setting.

Frequently Asked Questions (FAQ)

Common questions about Becebuen (FAQ)

Q: Can Becebuen cause drowsiness or fatigue?

A: Official product information states that the medicine may cause dizziness or drowsiness due to its reported effects on the central nervous system. This is described as a possible adverse reaction in the official documentation.

Q: Does taking Becebuen make you gain weight?

A: Official information indicates that unexplained weight gain or swelling, known as edema, is a reported adverse effect. This reported adverse effect is sometimes associated with fluid retention or potential effects on kidney function, according to official information.

Q: Are there any common foods or drinks that interact with Becebuen?

A: The regulatory label explicitly restricts co-administration with alcohol (ethanol). This is because alcohol may potentiate the central nervous system depressant effects of the drug's anticholinergic component.

Q: Has Becebuen been studied a lot by researchers?

A: Regulatory documents detail the core Phase 3 and extension clinical trials which established the drug's profile and support its official characteristics. While this evidence base is defined, the official documents do not typically quantify the total volume of all research conducted.

Q: What kind of warning label does Becebuen have?

A: The official label provides comprehensive safety instructions, including Contraindications (absolute prohibitions for use), Serious Adverse Reactions (SARs), and special precautions for patient groups. These precautions cover individuals with conditions such as pre-existing kidney or liver issues.

Q: Does Becebuen affect sleep patterns?

A: Sleep problems, such as insomnia, are reported in official documentation as a side effect. This is related to the drug's action on the nervous system.

Q: Are there any long-term health concerns linked to using Becebuen?

A: Due to the Non-Steroidal Anti-Inflammatory Drug (NSAID) component (Clonixin), official warnings indicate that prolonged use carries a risk of potential damage to the kidneys or liver. This is why regulatory bodies emphasize the need for regular professional monitoring during prolonged use.

Q: Is it true that Becebuen can affect mood?

A: Official reports indicate that the medicine may cause mood changes or alterations in mental status. These effects are reported to include depressive or anxious symptoms. Official documentation advises that any such changes in mental status be discussed with a healthcare professional.

Q: Is it normal to feel [Specific mild side effect] after starting Becebuen?

A: Official data lists common mild side effects as gastrointestinal issues (such as nausea and diarrhea) and headache. The incidence of these events is described in official product information; it is important to discuss any other persistent or concerning effects with a healthcare professional.

Q: What are the signs of a serious side effect from Becebuen I should be aware of?

A: Signs of a Serious Adverse Event (SAR) are detailed in the official product information. These include indications of a severe allergic reaction, such as a rash, severe swelling of the face or throat, or difficulty breathing, which are considered medical emergencies.

Q: Is Becebuen meant to be a short-term or long-term treatment?

A: The medicine is officially indicated for short-term, supportive symptom management. However, if use is required for a prolonged period, the regulatory label specifies that close monitoring is mandatory due to the presence of long-term risks.

Q: Do studies suggest Becebuen works equally well for all populations?

A: Primary clinical trials for Becebuen were conducted in adult participants. While the label notes that special caution is advised for older adults due to increased vulnerability to side effects, official labeling does not typically provide detailed summaries on efficacy differences across all demographics.

Q: How is Becebuen eliminated from the body?

A: The NSAID component of Becebuen, Clonixin, is primarily processed and eliminated from the body by the kidneys. The official documentation advises special caution for individuals with existing kidney issues, which is consistent with the primary elimination route.

Q: Does Becebuen interact with birth control pills?

A: The label warns against co-administration with strong CYP450 enzyme inducers. Since certain hormonal contraceptives are metabolized by this pathway, a healthcare professional must assess the potential risk of an interaction.

Q: Can I take Becebuen if I am currently taking an antidepressant?

A: The label warns against the concurrent use of the drug with other anticholinergic agents or certain CNS depressants. Since some antidepressants may fall into these categories, review with a healthcare professional is necessary to check all concomitant medicines.

Q: Is Becebuen safe to use while operating heavy machinery or driving?

A: Due to the reported risk of dizziness and drowsiness, the official label includes a warning to avoid operating heavy machinery or driving until one is familiar with how the medicine affects alertness and coordination.

Q: What happens if Becebuen is taken with grapefruit products?

A: Official information on the medicine's metabolism indicates that it uses the CYP450 enzyme system. As grapefruit products are known to inhibit this system, the potential risk of interaction must be assessed by a healthcare professional.

Q: Are there known interactions between Becebuen and herbal supplements?

A: Official documentation advises caution regarding substances that can affect the drug's action, such as other anticholinergic agents or CYP450 modifiers. Because some herbal supplements can affect these systems, the need for consultation with a healthcare professional is noted before use.

Q: Does Becebuen carry a Boxed Warning?

A: The official documentation for Becebuen clearly lists Contraindications and Severe Adverse Reactions. The specific requirement for a US-style 'Boxed Warning' is dependent on the regulatory jurisdiction of its approval and the overall assessment of the drug's highest level of risk.

How should Becebuen be stored and disposed of?

The official regulatory profile for Becebuen (Propinox/Clonixinato de Lisina) defines specific conditions for its storage to ensure stability.

Mandatory Storage Conditions

The medicine must be stored at ambient temperature, ensuring that the temperature does not exceed 30 C. Protection from moisture is required, meaning the product must be kept in a dry place.

Child-Safety and Disposal

It is officially mandated that Becebuen must be kept out of the sight and reach of children.

The regulatory label does not provide explicit instructions for discarding unused or expired product. Disposal should, therefore, be carried out according to local pharmaceutical waste regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Becebuen found in:

A-Z Index: